Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences, Tianjin, China.
Leuk Lymphoma. 2011 Jan;52(1):72-8. doi: 10.3109/10428194.2010.531411. Epub 2010 Dec 6.
Recently, a gene named TOSO was identified as being overexpressed and associated with the anti-apoptotic characteristic of chronic lymphocytic leukemia (CLL). However, the association of TOSO expression with clinical features of CLL has not been fully described, especially in Chinese patients. TOSO expression was detected by quantitative RT-PCR in CD19+ sorted cells in a cohort of 81 untreated patients with CLL. The results showed that the expression of TOSO in CLL was significantly higher than that in healthy controls (p = 0.027) and other B-cell lymphoproliferative diseases (p = 0.033). The expression level of TOSO was significantly correlated with Binet staging, IGVH mutation status, age, and time to treatment in CLL. A negative correlation was observed between age and TOSO expression (Spearman's, p = 0.025). No correlation was observed between the expression of TOSO and CD38 or ZAP-70. Cox regression analysis indicated that high expression of TOSO (more than 8.4) was an independent indicator for shorter treatment-free survival in CLL. We conclude that TOSO is specifically overexpressed and associated with progressive disease, and might be an important prognostic factor in CLL.
最近，一个名为 TOSO 的基因被鉴定为过度表达，并与慢性淋巴细胞白血病（CLL）的抗凋亡特征有关。然而，TOSO 表达与 CLL 的临床特征的关联尚未完全描述，特别是在中国患者中。在 81 例未经治疗的 CLL 患者的 CD19+分选细胞中，通过定量 RT-PCR 检测 TOSO 的表达。结果表明，CLL 中 TOSO 的表达明显高于健康对照组（p=0.027）和其他 B 细胞淋巴增生性疾病（p=0.033）。TOSO 的表达水平与 CLL 的 Binet 分期、IGHV 突变状态、年龄和治疗时间显著相关。TOSO 的表达与年龄呈负相关（Spearman's，p=0.025）。TOSO 的表达与 CD38 或 ZAP-70 之间无相关性。Cox 回归分析表明，TOSO 高表达（超过 8.4）是 CLL 无治疗生存时间较短的独立指标。我们得出结论，TOSO 特异性过表达与疾病进展相关，可能是 CLL 的一个重要预后因素。
